Development of Novel Small Molecule Anti-Fibrotic Agent for the Treatment of Systemic Scleroderma
治疗系统性硬皮病的新型小分子抗纤维化药物的开发
基本信息
- 批准号:10609109
- 负责人:
- 金额:$ 45.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-15 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:APLN geneAdipose tissueAffectAgonistAnimalsAnti-Inflammatory AgentsAntigensAreaAutoimmune ResponsesBiological AssayBiological MarkersBleomycinBlindedBody WeightCellsCessation of lifeChronicCicatrixCoculture TechniquesCollaborationsCollagenCutaneousDataDermalDevelopmentDiagnosisDiffuseDiseaseDisease modelDoseEndothelial CellsEndotheliumExtracellular MatrixFaceFailureFibrosisFundingGene ExpressionGene Expression ProfilingGoalsGrantHandHeartHistopathologyHumanHuman CharacteristicsHydroxyprolineImmuneImmune responseImmunosuppressive AgentsInflammationInjuryInterleukin-6InternationalInterstitial Lung DiseasesKidneyLeadLungLung Lavage FluidMeasurementMeasuresMediatingMedicalModelingMonoclonal AntibodiesMusMyocardial InfarctionOral AdministrationOrganOrgan Culture TechniquesOrphan DrugsOsmosisPathogenesisPathogenicityPathologistPathway interactionsPatientsPersonsPharmaceutical PreparationsPharmacologyPharmacotherapyPhasePhysical therapyProductionPrognosisPulmonary FibrosisPulmonary Function Test/Forced Expiratory Volume 1PumpQuality of lifeRare DiseasesRattusResearchRheumatismRiskRodent ModelSclerodermaSeverity of illnessSignal PathwaySkinSkin TissueSmall Business Technology Transfer ResearchStructure of parenchyma of lungSurrogate MarkersSystemSystemic SclerodermaSystemic TherapyTestingTherapeuticTherapeutic InterventionThickTissue ModelTissuesToxic effectTyrosine Kinase InhibitorUnited StatesVascular Endothelial CellVascular EndotheliumVascular regenerationWeightantifibrotic treatmentarmcell injurycell regenerationclinical candidatecytokinedisabilitydisorder subtypedrug candidatedrug developmentefficacy studyendothelial regenerationendothelial repairhigh riskhuman tissueidiopathic pulmonary fibrosisimprovedin vivoloss of functionmortalitymortality riskmouse modelnintedanibnovelnovel therapeuticspre-clinicalpreventprimary endpointreceptorregenerativerenal damagerepairedresponseresponse biomarkerskin fibrosissmall moleculesuccesssymptom treatmenttocilizumab
项目摘要
ABSTRACT
The goal of this STTR proposal is to develop a novel anti-fibrotic agent suitable for oral administration which
could be used to safely and effectively treat Systemic Sclerosis (SSc), or Systemic Scleroderma patients. SSc
is one of the most disabling and lethal immune-mediated rheumatic disorders. SSc is a rare disease, affecting
40,000-150,000 people in the United States and conferring a five to eight-fold higher risk for mortality. It is a
heterogeneous, multiorgan disease characterized by vascular endothelial alterations that results in chronic
inflammation and immune responses leading to progressive fibrosis and organ(s) failure. Major impacted organs
are skin, lungs, kidneys, and vasculature system. In SSc patients, vascular endothelial cell injury
characteristically precedes inflammation and autoimmune responses that stimulates the progression into tissue
fibrosis scaring. The leading cause of early death (5 years from diagnosis) is interstitial lung disease (ILD).
Treatment routinely relies on Nintedanib (TK inhibitor) and Tocilizumab (IL-6 mAb), and symptomatic treatments
but these have limited efficacy, and tolerability and/or toxicity issues. As of today, disease fibrosis progression
and mortality rate for SSc remains greater than for any other rheumatic disease; highlighting the clear unmet
medical need for disease modifying therapies that will prevent or reduce the damage to major organs. Targeting
repair and regeneration of the vascular endothelial cell injury via the Apelinergic System (apelin/APJ) signaling
pathway provides a unique and novel opportunity for the treatment of SSc patients (as of today vascular
endothelium repair and regeneration is an under targeted area in SSc drug development). The system is well-
established as an endogenous anti-injury and organ-protective mechanism that is activated post vascular
endothelium injury and is expressed in all SSc disease impacted organs.
APIE Therapeutics, in collaboration with RTI International, has identified a lead anti-fibrotic drug
candidate, apelin agonist APT101, for the treatment of lung fibrosis. First, in a bleomycin-induced lung fibrosis
mouse model therapeutic treatment with APT101 significantly inhibited the production of collagen in the lungs (a
hallmark of lung fibrosis progression), as detected via the Hydroxyproline Assay, and primary end point of the
study. Second, APT101 showed significantly reduced fibrosis in myocardial infarction animal studies (mice and
rats) and significantly reduced biomarker responses in ex-vivo human cell co-culture disease models relevant to
lung, skin, and kidney fibrotic diseases. Taken together, this evidence suggests that activation of the apelinergic
system has the potential to disrupt the pathogenic cascade responsible for progressive fibrosis in SSc. Our aims
for this proposal are obtain preclinical data in validated SSc models: 1) in-vivo efficacy model and, 2) ex-vivo
human tissue model. The results from Aims 1 and 2 will inform a data driven decision regarding APT101 IND
initial indication and subsequent plans for Phases II proposal.
摘要
该STTR提案的目标是开发一种适合口服给药的新型抗纤维化剂,
可以安全有效地治疗系统性硬化症(SSc)或系统性硬皮病患者。SSC
是最致残和致命的免疫介导的风湿性疾病之一。SSc是一种罕见的疾病,
在美国有40,000 - 150,000人,死亡风险高出5到8倍。这是一个
以血管内皮改变为特征的异质性多器官疾病,
炎症和免疫反应导致进行性纤维化和器官衰竭。主要受影响器官
是皮肤、肺、肾和脉管系统。在SSc患者中,
特征性地先于炎症和自身免疫反应,其刺激向组织中的进展。
纤维化疤痕早期死亡(诊断后5年)的主要原因是间质性肺病(ILD)。
治疗常规依赖于NATRA(TK抑制剂)和Tocilizumab(IL-6 mAb)以及对症治疗
但是这些药物的功效有限,并且存在耐受性和/或毒性问题。截至今天,疾病纤维化进展
SSc的死亡率仍然高于任何其他风湿性疾病;突出了明显的未满足的
医学上需要改善疾病的治疗,以防止或减少对主要器官的损害。靶向
通过Apelin能系统(apelin/APJ)信号传导修复和再生血管内皮细胞损伤
该途径为SSc患者的治疗提供了独特和新颖的机会(截至今天,血管性硬化症患者的治疗是一个新的途径)。
内皮修复和再生是SSc药物开发中的一个靶向不足的领域)。系统很好-
作为一种内源性抗损伤和器官保护机制,在血管后被激活,
内皮损伤,并在所有SSc疾病影响的器官中表达。
APIE Therapeutics与RTI International合作,确定了一种领先的抗纤维化药物
候选物,爱帕琳激动剂APT 101,用于治疗肺纤维化。首先,在博莱霉素诱导的肺纤维化中,
用APT 101进行的小鼠模型治疗性处理显著抑制了肺中胶原蛋白的产生(a
肺纤维化进展的标志),如通过羟脯氨酸测定所检测的,以及
study.第二,在心肌梗塞动物研究(小鼠和小鼠)中,APT 101显示出显著减少的纤维化。
大鼠)和显著降低的生物标志物应答,
肺、皮肤和肾纤维化疾病。综上所述,这些证据表明,激活apelinergic
系统有可能破坏导致SSc进行性纤维化的致病级联反应。我们的目标
对于该提案,在经验证的SSc模型中获得临床前数据:1)体内功效模型和2)离体
人体组织模型目的1和2的结果将为关于APT 101 IND的数据驱动决策提供信息
第二阶段提案的初步指示和后续计划。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Esther M Alegria其他文献
Esther M Alegria的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Deciphering the role of adipose tissue in common metabolic disease via adipose tissue proteomics
通过脂肪组织蛋白质组学解读脂肪组织在常见代谢疾病中的作用
- 批准号:
MR/Y013891/1 - 财政年份:2024
- 资助金额:
$ 45.24万 - 项目类别:
Research Grant
ESTABLISHING THE ROLE OF ADIPOSE TISSUE INFLAMMATION IN THE REGULATION OF MUSCLE MASS IN OLDER PEOPLE
确定脂肪组织炎症在老年人肌肉质量调节中的作用
- 批准号:
BB/Y006542/1 - 财政年份:2024
- 资助金额:
$ 45.24万 - 项目类别:
Research Grant
Canadian Alliance of Healthy Hearts and Minds: Dissecting the Pathways Linking Ectopic Adipose Tissue to Cognitive Dysfunction
加拿大健康心灵联盟:剖析异位脂肪组织与认知功能障碍之间的联系途径
- 批准号:
479570 - 财政年份:2023
- 资助金额:
$ 45.24万 - 项目类别:
Operating Grants
Determinants of Longitudinal Progression of Adipose Tissue Inflammation in Individuals at High-Risk for Type 2 Diabetes: Novel Insights from Metabolomic Profiling
2 型糖尿病高危个体脂肪组织炎症纵向进展的决定因素:代谢组学分析的新见解
- 批准号:
488898 - 财政年份:2023
- 资助金额:
$ 45.24万 - 项目类别:
Operating Grants
Activation of human brown adipose tissue using food ingredients that enhance the bioavailability of nitric oxide
使用增强一氧化氮生物利用度的食品成分激活人体棕色脂肪组织
- 批准号:
23H03323 - 财政年份:2023
- 资助金额:
$ 45.24万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of new lung regeneration therapies by elucidating the lung regeneration mechanism of adipose tissue-derived stem cells
通过阐明脂肪组织干细胞的肺再生机制开发新的肺再生疗法
- 批准号:
23K08293 - 财政年份:2023
- 资助金额:
$ 45.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A study on the role of brown adipose tissue in the development and maintenance of skeletal muscles
棕色脂肪组织在骨骼肌发育和维持中作用的研究
- 批准号:
23K19922 - 财政年份:2023
- 资助金额:
$ 45.24万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Adipose Tissue T Cell Polarization and Metabolic Health in Persons Living with HIV
HIV 感染者的脂肪组织 T 细胞极化和代谢健康
- 批准号:
10619176 - 财政年份:2023
- 资助金额:
$ 45.24万 - 项目类别:
Estrogen Signaling in the Ventromedial Hypothalamus Modulates Adipose Tissue Metabolic Adaptation
下丘脑腹内侧区的雌激素信号调节脂肪组织代谢适应
- 批准号:
10604611 - 财政年份:2023
- 资助金额:
$ 45.24万 - 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
- 批准号:
10813753 - 财政年份:2023
- 资助金额:
$ 45.24万 - 项目类别: